The effects of methamphetamine on electrocardiographic parameters in male patients.
Bahadir Demir, Filiz Ozsoy, Ahmet Buyuk...
https://pubmed.ncbi.nlm.nih.gov/35225724/Actively Recruiting
Led by Elazığ Mental Health and Diseases Hospital · Updated on 2026-09-10
240
Participants Needed
1
Research Sites
7 weeks
Total Duration
Researchers are studying adults diagnosed with Methamphetamine Use Disorder MUD and Methamphetamine-Induced Psychotic Disorder MP to compare electrocardiogram ECG results and assess whether psychosis linked to methamphetamine use increases heart risks. This observational study takes place during inpatient psychiatric treatment, focusing on heart electrical activity differences between those with and without psychosis related to methamphetamine use. Participants include adults aged 18 to 65 diagnosed with MUD or MP, as well as a healthy control group without psychiatric disorders. All participants undergo routine clinical care without additional interventions from the study. ECGs and blood tests are performed at hospital admission and after six weeks of treatment. The MP group also receives assessments for psychotic symptom severity and insight level using standard scales. During the study, participants provide sociodemographic and clinical information. ECGs are reviewed by a cardiologist to identify abnormalities, and psychiatric symptoms are measured in the MP group. The main measure is ECG changes at admission and after six weeks. Additional outcomes include blood counts and psychometric scores. The study aims to understand heart health risks related to methamphetamine use and psychosis by comparing participants over six weeks of inpatient care.
CONDITIONS
ECG Findings in Methamphetamine Use
M
Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Elazığ Mental Health and Diseases Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo initial clinical assessments including electrocardiogram (ECG), complete blood count, and psychometric evaluations if applicable.
1 visit (in-person)
Duration - 6 weeks
Participants receive routine psychiatric inpatient care. ECG and blood tests are repeated after six weeks. Psychotic symptom severity and insight are assessed in the MP group.
2 visits (baseline and 6 weeks)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Bahadir Demir, Filiz Ozsoy, Ahmet Buyuk...
https://pubmed.ncbi.nlm.nih.gov/35225724/Christopher G Kevil, Nicholas E Goeders, Matthew D Woolard...
https://pubmed.ncbi.nlm.nih.gov/31433698/Valentin Schwarzbach, Karsten Lenk, Ulrich Laufs
https://pubmed.ncbi.nlm.nih.gov/31950731/Kelly E Courtney, Lara A Ray
https://pubmed.ncbi.nlm.nih.gov/25176528/Suzette Glasner-Edwards, Larissa J Mooney
https://pubmed.ncbi.nlm.nih.gov/25373627/Elazığ Mental Health and Diseases Hospital
Lead Sponsor